Literature DB >> 7473817

Determinants of black/white differences in colon cancer survival.

R M Mayberry1, R J Coates, H A Hill, L A Click, V W Chen, D F Austin, C K Redmond, C M Fenoglio-Preiser, C P Hunter, M A Haynes.   

Abstract

BACKGROUND: Blacks have lower survival rates for colon cancer than whites, possibly related to more advanced stages of disease at diagnosis and to socioeconomic differences between blacks and whites. While the black/white difference in colon cancer survival is well documented, the few studies that have investigated this difference have been limited by the modest number and type of explanatory factors that were considered.
PURPOSE: We analyzed data from the National Cancer Institute Black/White Cancer Survival Study to determine 1) what characteristics might contribute to the racial difference in colon cancer survival and 2) if a survival disparity remained between black and white patients after adjustment was made for these characteristics.
METHODS: This prospective study included 454 blacks and a stratified random sample of 521 whites, aged 20-79 years, with cancer of the colon diagnosed from January 1, 1985, through December 31, 1986, and who were residents of the metropolitan areas of Atlanta, New Orleans, and San Francisco/Oakland. Follow-up was truncated on December 31, 1990. Cox proportional hazards regression was used to estimate the death rate among blacks relative to that among whites after adjustment for potential explanatory factors, including sociodemographic factors, concurrent (comorbid) medical conditions, stage at diagnosis, tumor characteristics, and treatment. All P values were calculated from two-tailed tests of statistical significance.
RESULTS: After adjustment for age, sex, and geographic area, the black-to-white mortality hazard ratio (HR) was 1.5 (95% confidence interval [CI] = 1.2-1.9), indicating that the risk of death among black patients was 50% higher than that among white patients. Further adjustment for stage reduced the excess cancer mortality to 20% (HR = 1.2; 95% CI = 1.0-1.5), decreasing the overall racial difference in excess mortality from 50% to 20% or to a 60% reduction in excess mortality. Although adjustment for poverty reduced the excess mortality by 20%, adjusting for both stage and poverty did not further reduce the racial difference. Among patients with stages II and III disease, blacks had lower survival rates than whites (HR = 1.8; 95% CI = 1.0-3.1 and HR - 1.5; 95% CI = 1.0-2.3, respectively). Among those patients with metastatic disease (stage IV), survival was similar for whites and blacks.
CONCLUSIONS: Stage at diagnosis accounted for more than half of the excess colon cancer mortality observed among blacks. Poverty and other socioeconomic conditions, general health status, tumor characteristics, and general patterns of treatment did not further explain the remaining survival disadvantage among blacks. IMPLICATIONS: Because the racial disparity was confined to earlier stages, future studies should investigate whether blacks have more advanced disease at diagnosis and whether less aggressive treatment is provided because of understanding.

Entities:  

Mesh:

Year:  1995        PMID: 7473817     DOI: 10.1093/jnci/87.22.1686

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  71 in total

1.  Lower albumin levels in African Americans at colon cancer diagnosis: a potential explanation for outcome disparities between groups?

Authors:  Aja S McCutchen; Juan Carlos Munoz; Lacie Brenner; Peter Wludyka; Kenneth J Vega
Journal:  Int J Colorectal Dis       Date:  2011-01-27       Impact factor: 2.571

2.  Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma.

Authors:  Dominik Alexander; Chakrapani Chatla; Ellen Funkhouser; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

3.  Racial disparities in stage-specific colorectal cancer mortality: 1960-2005.

Authors:  Samir Soneji; Shally Shalini Iyer; Katrina Armstrong; David A Asch
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

4.  High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas.

Authors:  Dominik Alexander; Nirag Jhala; Chakrapani Chatla; Jon Steinhauer; Ellen Funkhouser; Christopher S Coffey; William E Grizzle; Upender Manne
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

5.  Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.

Authors:  Rui Gao; Douglas K Price; Tristan Sissung; Eddie Reed; William D Figg
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

6.  Laparoscopic vs open colectomy for colon cancer: results from a large nationwide population-based analysis.

Authors:  Scott R Steele; Tommy A Brown; Robert M Rush; Matthew J Martin
Journal:  J Gastrointest Surg       Date:  2007-09-07       Impact factor: 3.452

7.  Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.

Authors:  Terry Hyslop; David S Weinberg; Stephanie Schulz; Alan Barkun; Scott A Waldman
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

8.  Increasing Disparity in Colorectal Cancer Incidence and Mortality Among African Americans and Whites: A State's Experience.

Authors:  Noelle K Loconte; Amy Williamson; Arlene Gayle; Jennifer Weiss; Ticiana Leal; Jeremy Cetnar; Tabraiz Mohammed; Amye Tevaarwerk; Nathan Jones
Journal:  J Gastrointest Oncol       Date:  2011

Review 9.  Guanylyl cyclase C as a biomarker in colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

10.  Colorectal cancer: epidemiology, risk factors, and health services.

Authors:  Farin Amersi; Michelle Agustin; Clifford Y Ko
Journal:  Clin Colon Rectal Surg       Date:  2005-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.